pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
1. A pharmaceutical composition formulated for oral administration comprising a suspension of a crystalline solid, biologically active agent in a non-aqueous liquid carrier, wherein the weight ratio of said active agent to said non-aqueous liquid carrier is between about 50:1 and about 1:10, wherein the pharmaceutical composition is a solid-in-oil suspension that is substantially free of water and wherein the non-aqueous carrier is an oil wherein:
(a) the carrier comprises at least 10 wt % of free monocarboxylic acid having at least 8 carbons, wherein the monocarboxylic acid is liquid at room temperature;
(b) the carrier comprises from about 0.0001 wt. % to about 5 wt. % of zwitterionic phospholipids; and
(c) the pharmaceutical composition releases a lesser amount of active agent at a pH of <3 than at pH >3,
wherein the composition is formulated in the absence of a solvent.
2. The pharmaceutical composition of claim 1 , wherein less than 20% of the biologically active agent is released from the non-aqueous liquid carrier at pH <3 and greater than 50% of the biologically active agent is released from the non-aqueous liquid carrier at pH >3.
3. The pharmaceutical composition of claim 1 , wherein the non-aqueous liquid carrier releases a lesser amount of biologically active agent at pH <5 than at pH >5.
4. The pharmaceutical composition of claim 1 , wherein the biologically active agent comprises at least one agent selected from the group consisting of an acid-labile pharmaceutical agent, an anti-depressant, an anti-diabetic agent, an anti-epileptic agent, an anti-fungal agent, an anti-malarial agent, an anti-muscarinic agent, an anti-neoplastic agent, an immunosuppressant, an anti-protozoal agent, an anti-tussive, a neuroleptics, a beta-blocker, a cardiac inotropic agent, a corticosteroid, an anti-parkinsonian agent, a gastrointestinal agent, histamine, a histamine receptor antagonist, a keratolytic, a lipid regulating agent, a muscle relaxant, a nitrate, an anti-anginal agent, a nutritional agent, an opioid analgesic, a sex hormone, a stimulant, a nutraceutical, a peptide, a protein, a therapeutic protein, a nucleoside, a nucleotide, DNA, RNA, a glycosaminoglycan, an acid-labile drug, (+)-N{3-[3-(4-fluorophenoxy)phenyl]-2-cyclopenten-1-yl}-Nhydroxyurea, amylase, aureomycin, bacitracin, beta carotene, cephalosporins, chloromycetin, cimetidine, cisapride, cladribine, clorazepate, deramciclane, didanosine, digitalis glycosides, dihydrostreptomycin, erythromycin, etoposide, famotidine, a hormone, estrogen, insulin, adrenalin, heparin, lipase, milameline, novobiocin, pancreatin, penicillin salts, polymyxin, pravastatin, progabide, protease, quinapril, quinoxaline-2-carboxylic acid, [4-(R)carbamoyl-1-(S-3-fluorobenzyl-2-(S),7-dihydroxy-7-methyloctyl]amide-, quinoxaline-2-carboxylic acid[1-benzyl-4-(4,4-difluoro-1-hydroxy-cyclohexyl)-2-hydroxy-4-hydroxyca-rbamoyl-butyl]-amide, ranitidine, streptomycin, subtilin, sulphanilamide, a proton pump inhibitors, esomeprazole, lansoprazole, minoprazole, omeprazole, pantoprazole and rabeprazole.
5. The pharmaceutical composition of claim 4 , wherein the biologically active agent is an acid-labile drug.
6. The pharmaceutical composition of claim 5 , wherein the acid-labile drug is selected from the group consisting of heparin, insulin, erythropoietin, pancreatin, lansoprazole, omeprazole, pantoprazole, rabeprazole, penicillin salts, benzathine penicillin, polymyxin, sulphanilamide, and erythromycin.
7. The pharmaceutical composition of claim 1 , wherein the non-aqueous liquid carrier further comprises at least one component selected from the group consisting of an adjuvant, a mixture of adjuvants, an antioxidant, a mixture of antioxidants, a viscomodulator, a mixture of viscomodulators, and a permeability-improving agent.
8. The pharmaceutical composition of claim 1 , wherein the monocarboxylic acid is a medium chain free fatty acid or a very-long-chain free fatty acid.
9. The pharmaceutical composition of claim 1 , wherein the monocarboxylic acid is unsaturated.
10. The pharmaceutical composition of claim 1 , wherein the weight ratio of active agent to carrier is between about 25:1 and about 1:5.
11. The pharmaceutical composition of claim 1 , wherein the weight ratio of active agent to carrier is between about 25:1 and about 1:1.
12. The pharmaceutical composition of claim 1 , wherein the non-aqueous liquid carrier is substantially free of fatty acid salt.
13. A pharmaceutical composition of a biologically active agent made by admixing a solid biologically active agent into a non-aqueous liquid carrier, wherein the composition is formulated for oral administration, wherein the weight ratio of said active agent to said non-aqueous liquid carrier is between about 50:1 and about 1:10, and wherein the non-aqueous liquid carrier is an oil wherein:
(a) the carrier comprises at least about 10 wt % of a free monocarboxylic acid having at least 8 carbons, wherein the monocarboxylic acid is liquid at room temperature;
(b) the carrier is substantially free of water;
(c) the carrier comprises from about 0.0001 wt. % to about 5 wt. % of zwitterionic phospholipids; and
(d) the pharmaceutical composition releases a lesser amount of active agent at a pH of
<3 than at pH >3,
wherein the composition is formulated in the absence of a solvent.
14. The pharmaceutical composition of claim 13 , wherein the solid biologically active agent comprises crystals of the biologically active agent.
15. The pharmaceutical composition of claim 13 , wherein:
(a) less than about 20% of the biologically active agent is released from the non-aqueous liquid carrier at pH <3; and
(b) greater than about 50% of the biologically active agent is released from the non-aqueous liquid carrier at pH >3.
16. The pharmaceutical composition of claim 13 , wherein the biologically active agent comprises at least one agent selected from the group consisting of an acid-labile pharmaceutical agent, an anti-depressant, an anti-diabetic agent, an anti-epileptic agent, an anti-fungal agent, an anti-malarial agent, an anti-muscarinic agent, an anti-neoplastic agent, an immunosuppressant, an anti-protozoal agent, an anti-tussive, a neuroleptics, a betablocker, a cardiac inotropic agent, a corticosteroid, an anti-parkinsonian agent, a gastrointestinal agent, histamine, a histamine receptor antagonist, a keratolytic, a lipid regulating agent, a muscle relaxant, a nitrate, an anti-anginal agent, a nutritional agent, an opioid analgesic, a sex hormone, a stimulant, a nutraceutical, a peptide, a protein, a therapeutic protein, a nucleoside, a nucleotide, DNA, RNA, a glycosaminoglycan, an acid-labile drug, (+)-N{3-[3-(4-fluorophenoxy)phenyl]-2-cyclopenten-1-yl}-N-hydroxyurea, amylase, aureomycin, bacitracin, beta carotene, cephalosporins, chloromycetin, cimetidine, cisapride, cladribine, clorazepate, deramciclane, didanosine, digitalis glycosides, dihydrostreptomycin, erythromycin, etoposide, famotidine, a hormone, estrogen, insulin, adrenalin, heparin, lipase, milameline, novobiocin, pancreatin, penicillin salts, polymyxin, pravastatin, progabide, protease, quinapril, quinoxaline-2-carboxylic acid, [4-(R)carbamoyl-1-(S-3-fluorobenzyl-2-(S), 7-dihydroxy-7-methyloctyl]amide-, quinoxaline-2-carboxylic acid[1-benzyl-4-(4,4-difluoro-1-hydroxy-cyclohexyl)-2-hydroxy-4-hydroxycarbamoyl-butyl]-amide, ranitidine, streptomycin, subtilin, sulphanilamide, a proton pump inhibitors, esomeprazole, lansoprazole, minoprazole, omeprazole, pantoprazole and rabeprazole.
17. The pharmaceutical composition of claim 16 , wherein the biologically active agent is an acid-labile drug.
18. The pharmaceutical composition of claim 17 , wherein the acid-labile drug is selected from the group consisting of heparin, insulin, erythropoietin, pancreatin, lansoprazole, omeprazole, pantoprazole, rabeprazole, penicillin salts, benzathine penicillin, polymyxin, sulphanilamide, and erythromycin.
19. The pharmaceutical composition of claim 13 , wherein the non-aqueous liquid carrier further comprises at least one component selected from the group consisting of an adjuvant, a mixture of adjuvants, an antioxidant, a mixture of antioxidants, a viscomodulator, a mixture of viscomodulators, and a permeability-improving agent.
20. The pharmaceutical composition of claim 13 , wherein the monocarboxylic acid is a medium chain free fatty acid or a very-long-chain free fatty acid.
21. The pharmaceutical composition of claim 13 , wherein the monocarboxylic acid is unsaturated.
22. The pharmaceutical composition of claim 13 , wherein the weight ratio of active agent to carrier is between about 25:1 and about 1:5.
23. The pharmaceutical composition of claim 13 , wherein the weight ratio of active agent to carrier is between about 25:1 and about 1:1.
24. The pharmaceutical composition of claim 13 , wherein the non-aqueous liquid carrier is substantially free of fatty acid salt.